PLoS By Category | Recent PLoS Articles

Biochemistry - Biotechnology - Oncology - Pharmacology - Radiology and Medical Imaging

DW-MRI as a Biomarker to Compare Therapeutic Outcomes in Radiotherapy Regimens Incorporating Temozolomide or Gemcitabine in Glioblastoma
Published: Friday, April 20, 2012
Author: Stefanie Galbán et al.

by Stefanie Galbán, Benjamin Lemasson, Terence M. Williams, Fei Li, Kevin A. Heist, Timothy D. Johnson, Judith S. Leopold, Thomas L. Chenevert, Theodore S. Lawrence, Alnawaz Rehemtulla, Tom Mikkelsen, Eric C. Holland, Craig J. Galbán, Brian D. Ross

The effectiveness of the radiosensitizer gemcitabine (GEM) was evaluated in a mouse glioma along with the imaging biomarker diffusion-weighted magnetic resonance imaging (DW-MRI) for early detection of treatment effects. A genetically engineered murine GBM model [Ink4a-Arf-/- PtenloxP/loxP/Ntv-a RCAS/PDGF(+)/Cre(+)] was treated with gemcitabine (GEM), temozolomide (TMZ) +/- ionizing radiation (IR). Therapeutic efficacy was quantified by contrast-enhanced MRI and DW-MRI for growth rate and tumor cellularity, respectively. Mice treated with GEM, TMZ and radiation showed a significant reduction in growth rates as early as three days post-treatment initiation. Both combination treatments (GEM/IR and TMZ/IR) resulted in improved survival over single therapies. Tumor diffusion values increased prior to detectable changes in tumor volume growth rates following administration of therapies. Concomitant GEM/IR and TMZ/IR was active and well tolerated in this GBM model and similarly prolonged median survival of tumor bearing mice. DW-MRI provided early changes to radiosensitization treatment warranting evaluation of this imaging biomarker in clinical trials.